Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

NCT07687875 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer Patients

Interventions

DRUG: BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody)

Sponsor

Henry Smith

Collaborators

[object Object]
[object Object]